sign in sign up
<<
Home , Alogliptin

Nesina™ (), Kazano™ (alogliptin/), Oseni ™ (alogliptin/ ) – First-time Generics • Perrigo plans to launch the authorized generic versions of Takeda’s Nesina (alogliptin), Kazano (alogliptin/metformin), and Oseni (alogliptin/pioglitazone) in April 2016.

• Nesina, Kazano and Oseni are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

• Nesina is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and it is available as 6.25 mg, 12.5 mg and 25 mg tablets.

— Other oral DPP-4 inhibitors include Onglyza® (), Januvia ® (), and Tradjenta® (). These are currently only available as brand products.

• Kazano and Oseni are alogliptin-containing combination products.

• Kazano contains alogliptin and metformin, a agent. It is available as 12.5 mg/500 mg and 12.5 mg/1000 mg tablets.

— Other oral DPP-4 inhibitor/biguanide combination products include Janumet® (sitagliptin/metformin), Janumet® XR (sitagliptin/metformin extended-release), Jentadueto® (linagliptin/metformin), and Kombiglyze™ XR (saxagliptin/metformin extended-release). These are currently only available as brand products.

• Oseni contains alogliptin and pioglitazone, a . It is available as 12.5 mg/15 mg, 12.5 mg/30 mg, 12.5 mg/45 mg, 25 mg/15 mg, 25 mg/30 mg, and 25 mg/45 mg tablets.

• The individual components in Kazano and Oseni are also available as distinct products.

• Boxed warnings for Kazano and Oseni include lactic acidosis and congestive , respectively.

optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com. All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx. Rx News® is published by the OptumRx Clinical Services Department. ©2016 Optum, Inc. All rights reserved.